Hoe verhoudt GSK's PE Ratio zich tot zijn concurrenten?

GSK is good value based on its Price-To-Earnings Ratio (23.1x) compared to the peer average (27.4x).

Hoe verhoudt GSK's PE Ratio zich tot andere bedrijven in de European Pharmaceuticals industrie?

GSK is expensive based on its Price-To-Earnings Ratio (23.1x) compared to the European Pharmaceuticals industry average (21.4x).

Wat is GSK's PE Ratio vergeleken met zijn Fair PE Ratio? Dit is de verwachte PE Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

GSK is good value based on its Price-To-Earnings Ratio (23.1x) compared to the estimated Fair Price-To-Earnings Ratio (38x).

Wat is de reële prijs van GSK als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

GSK (£14.2) is trading below our estimate of [[fair value]] (£51.73)

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

GSK (LSE:GSK) - Aandelenkoers, Nieuws & Analyse

GSK Overzicht aandelen

GSK plc houdt zich samen met haar dochterondernemingen bezig met onderzoek, ontwikkeling en productie van vaccins en speciale en algemene geneesmiddelen om ziekten te voorkomen en te behandelen in het Verenigd Koninkrijk, de Verenigde Staten en internationaal.

Over het bedrijf

GSK fundamentele analyse
Sneeuwvlok Score
Waardering	4/6
Toekomstige groei	5/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	2/6

Beloningen

Trading at 72.6% below our estimate of its fair value

Earnings are forecast to grow 21.66% per year

Risicoanalyse

Profit margins (8%) are lower than last year (20.5%)

Dividend of 4.09% is not well covered by earnings

Large one-off items impacting financial results

Has a high level of debt

GSK plc Concurrenten

AstraZeneca

LSE:AZN

UK£170.9b

Hikma Pharmaceuticals

LSE:HIK

UK£4.2b

Animalcare Group

AIM:ANCR

UK£143.7m

Merck KGaA

XTRA:MRK

€67.0b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor GSK
Historische aandelenkoersen
Huidige aandelenkoers	UK£14.20
52 Week Hoogtepunt	UK£18.24
52 Week Laag	UK£13.71
Bèta	0.31
11 maand verandering	-2.74%
3 maanden verandering	-6.70%
1 Jaar Verandering	1.03%
33 jaar verandering	-27.12%
5 jaar verandering	-33.91%
Verandering sinds IPO	-39.50%

Recent nieuws en updates

GSK plc (LON:GSK) Not Flying Under The Radar

Nov 02

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Nov 02

Recent updates

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

May 02

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

Apr 19

Rendement voor aandeelhouders

	GSK	GB Pharmaceuticals	GB Markt
7D	-2.2%	-4.4%	-1.3%
1Y	1.0%	5.6%	8.9%

Rendement versus industrie: GSK underperformed the UK Pharmaceuticals industry which returned 5.6% over the past year.

Rendement versus markt: GSK underperformed the UK Market which returned 8.9% over the past year.

Prijsvolatiliteit

Is GSK's price volatile compared to industry and market?
GSK volatility
GSK Average Weekly Movement	2.5%
Pharmaceuticals Industry Average Movement	6.8%
Market Average Movement	4.7%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.6%

Stabiele aandelenkoers: GSK has not had significant price volatility in the past 3 months compared to the UK market.

Volatiliteit in de loop van de tijd: GSK's weekly volatility (3%) has been stable over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1715	70,212	Emma Walmsley	www.gsk.com

GSK plc houdt zich, samen met haar dochterondernemingen, bezig met onderzoek, ontwikkeling en productie van vaccins en speciale en algemene geneesmiddelen om ziekten te voorkomen en te behandelen in het Verenigd Koninkrijk, de Verenigde Staten en internationaal. Het bedrijf opereert via twee segmenten, Commercial Operations en Total R&D. Het bedrijf biedt vaccins tegen gordelroos, meningitis, respiratoir syncytieel virus, griep, polio, influenza en pandemische vaccins.

GSK plc Samenvatting

Hoe verhouden de winst en inkomsten van GSK zich tot de beurswaarde?
GSK fundamentele statistieken
Marktkapitalisatie	UK£57.92b
Inkomsten(TTM)	UK£2.51b
Inkomsten(TTM)	UK£31.31b

23.1x

Koers/Winstverhouding

1.8x

P/S-verhouding

Is GSK overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GSK resultatenrekening (TTM)
Inkomsten	UK£31.31b
Kosten van inkomsten	UK£8.65b
Brutowinst	UK£22.67b
Overige uitgaven	UK£20.15b
Inkomsten	UK£2.51b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	0.62
Brutomarge	72.39%
Nettowinstmarge	8.02%
Schuld/Eigen Vermogen Verhouding	119.4%

Hoe presteerde GSK op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

4.1%

Huidig dividendrendement

99%

Uitbetalingsratio

Betaalt GSK een betrouwbaar dividend?

Zie GSK dividendgeschiedenis en benchmarks

Wanneer moet je GSK kopen om een aanstaand dividend te ontvangen?
GSK dividenddata
Ex Dividend Datum	Nov 14 2024
Betaaldatum dividend	Jan 09 2025
Dagen tot Ex-dividend	9 days
Dagen tot dividendbetaaldatum	65 days

Betaalt GSK een betrouwbaar dividend?

Zie GSK dividendgeschiedenis en benchmarks

GSK Overzicht aandelen

Beloningen

Risicoanalyse

GSK plc Concurrenten

LSE:AZN

UK£170.9b

LSE:HIK

UK£4.2b

AIM:ANCR

UK£143.7m

XTRA:MRK

€67.0b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

GSK plc (LON:GSK) Not Flying Under The Radar

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Third quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 15%

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

Recent updates

GSK plc (LON:GSK) Not Flying Under The Radar

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Third quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 15%

GSK plc Announces New Positive Arexvy Data in Younger Adults At Risk

GSK plc Announces US Food and Drug Administration Accepts New Drug Application for Treatment of Uncomplicated Urinary Tract Infections in Female Adults and Adolescents

GSK plc Announces Positive Headline Results from the Phase III Clinical Trials ANCHOR-1 and ANCHOR-2

Roche/Genentech's Gazyva Poised to Transform Lupus Nephritis Treatment After Positive Phase III Results

GSK plc Presents Positive Data for Arexvy, its Respiratory Syncytial Virus Vaccine

Gsk Plc's Menveomeningococcal Vaccine in New Single-Vial, Fully Liquid Presentation Receives Positive European Chmp Opinion

GSK plc Reaches Two Confidential Settlements in Cases Filed in California State Court with John Russell

GSK plc Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme

GSK plc Reaches Confidential Settlement in Zantac Litigation with Isaac Dixon

GSK plc Provides Update on Phase I/II Therapeutic Herpes Simplex Virus Vaccine Trial

Does GSK (LON:GSK) Have A Healthy Balance Sheet?

GSK plc Announces European Commission Has Authorised Arexvy for Active Immunisation for the Prevention of Lower Respiratory Tract Disease

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Receives US Food and Drug Administration Breakthrough Therapy Designation for GSK5764227

Gsk plc Announces Zantac (Ranitidine) Litigation Update

GSK plc Announces Zantac (Ranitidine) Litigation Update

GSK (LON:GSK) Is Paying Out A Dividend Of £0.15

Second quarter dividend of UK£0.15 announced

GSK plc Announces US FDA Expands Jemperli (Dostarlimab-Gxly) Plus Chemotherapy Approval to All Adult Patients with Primary Advanced or Recurrent Endometrial Cancer as the First and Only Immuno-Oncology-Based Treatment to Show an Overall Survival Benefit

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Declares Second Interim Dividend for Second Quarter of 2024, Payable on 10 October 2024

GSK plc Announces Blenrep EMA Filing Acceptance

GSK plc Begins Shipping Influenza Vaccine Doses for 2024-25 Season

GSK's Omjjara (Momelotinib) Receives Approval in Japan for Treatment of Myelofibrosis

iTeos Therapeutics, Inc. and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

GSK plc Announces That the US Food and Drug Administration (FDA) Has Approved Arexvy

GSK plc (LSE:GSK) acquired Elsie Biotechnologies for $50 million.

GSK plc Announces Positive Results from an Interim Analysis of the DREAMM-8 Phase III Head-To-Head Trial Evaluating Belantamab Mafodotin

GSK plc Provides Litigation Update

An unknown buyer intended to acquire 4.2% stake in Haleon plc (LSE:HLN) from GSK plc (LSE:GSK) for £1.2 billion.

GSK Announces Intention to Sell Approximately 385 Million Shares in Haleon

Gsk plc Announces Board Committee Changes

GSK (LON:GSK) Will Pay A Dividend Of £0.15

First quarter dividend of UK£0.15 announced

GSK plc to Report Q2, 2024 Results on Jul 31, 2024

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For GSK plc's (LON:GSK) CEO For Now

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

GSK plc Samenvatting

23.1x

1.8x

Inkomsten en omzet

Dividenden

4.1%

99%